Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chunkang Xuezhi Capsule is a Mongolian medicine developed by Inner Mongolia Aoteqi Mongolian Medicine Co., Ltd. for the treatment of primary hyperlipidemia. It is specifically indicated for patients presenting with the traditional Chinese medicine (TCM) and Mongolian medicine pattern of 'liver-spleen-kidney deficiency with phlegm and blood stasis.' The formulation is designed to regulate lipid metabolism, resolve phlegm, and remove blood stasis. It has been evaluated in Phase II randomized, double-blind, placebo-controlled clinical trials in China to assess its efficacy and safety in adults with primary hyperlipidemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chunkang Xuezhi Capsule.